Absorption: 60% absorbed following oral administration; 100% absorbed from IM sites.
Distribution: Unknown.
Protein Binding: 99%; potential for drug interactions due to drug displacement is minimal.
Metabolism/Excretion: 99% metabolized by the liver; <1% excreted unchanged in urine.
Half-life: PO 7 hr; IM 25 hr.
Contraindicated in:
Use Cautiously in:
CV: orthostatic hypotension, QT interval prolongation.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME (SJS), rash, urticaria.
Endo: galactorrhea, hyperglycemia, hyperlipidemia, weight gain.
GI: constipation, diarrhea, nausea, dysphagia.
GU: amenorrhea, impotence.
Hemat: AGRANULOCYTOSIS, leukopenia, neutropenia.
Neuro: NEUROLEPTIC MALIGNANT SYNDROME, seizures, dizziness, drowsiness, restlessness, extrapyramidal reactions, syncope, tardive dyskinesia.
Resp: cough, rhinorrhea.
Drug-Drug:
Schizophrenia
Acute Manic or Mixed Episodes Associated with Bipolar I Disorder
Maintenance Treatment of Bipolar I Disorder (as adjunct to lithium or valproate)
(Generic available)
NDC Code*